title: Novel therapies for aggressive B-cell lymphoma.
abstract: Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.
authors.affiliation: Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA.
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Foon
authors.forename: Kenichi
authors.initials: K
authors.lastname: Takeshita
authors.forename: Pier L
authors.initials: PL
authors.lastname: Zinzani